sis are severely immunocompromised irrespective of therapeutic immunomodulation [6] .
In this issue of Respiration , Ikezoe et al. [7] assessed the prevalence of chronic kidney disease (CKD) and its correlation with parameters of disease progression and mortality in a moderately sized cohort of patients with IPF ( n = 123). The authors used as a control group a cohort of patients with chronic obstructive pulmonary disease. Intriguingly, CKD was equally prevalent in patients with IPF and in those with chronic obstructive pulmonary disease (30 vs. 23%). Patients with CKD and IPF demonstrated a worse prognosis than those without CKD. More importantly, clinical measures of CKD severity, such as glomerular filtration rate, showed a strong and independent association with unfavorable outcomes in patients with IPF, as well as other parameters of disease progression, including age, %DL CO , and 6-minute walking distance. There are several novel and important attributes of this study that are worth being reported:
The prevalence of CKD in patients with IPF is strikingly high and has never been reported before. This evidence can be explained mechanistically by an accelerated aging process leading to several comorbidities within the spectrum of coronary artery disease and diabetes mellitus that may negatively regulate renal function. Drugs prescribed for some of these comorbidities, mainly diuretics, can also be associated with renal function impairment. In this cohort, patients with IPF and CKD were older and exhibited significantly higher prescription rates of diuretics "Thinking outside the box" entails a thinking process which involves the implementation of an unconventional approach to the rational thinking structure [1] . It implies the definition of creative thinking given that it rejects the procedural knowledge and the accepted paradigm to delineate new ideas.
Idiopathic pulmonary fibrosis (IPF) represents a disease paradigm of an abnormal wound healing process in response to repetitive injurious stimuli in genetically predisposed and aged individuals [2, 3] . Until recently, the dogma of lung-isolated fibrotic injury prevailed in the concept of a systemic inflammatory process, and, thus, comorbid conditions have been largely underappreciated. More recently, it has been proposed that many of the pathogenetic hallmarks of IPF, including telomere attrition, epigenetic modifications, mitochondrial dysfunction, genomic instability, and impaired nutrient sensing, can be explained by the role of aging [4] . As a disease paradigm of accelerated aging, IPF has been recently associated with major comorbidities that exert a major impact on disease mortality and progression [5] . These comorbidities include both pulmonary and extrapulmonary conditions, such as pulmonary hypertension, lung cancer, gastroesophageal reflux disease, sleep apnea, coronary artery disease, diabetes mellitus, hypothyroidism, depression, and general deconditioning [5] . Some of these comorbidities could also be explained in the context of systemic inflammation driven by an occult autoimmune process. Indeed, large genomic studies have demonstrated that patients with IPF who exhibit a dismal progno-than those without CKD, and this evidence should be taken into consideration. Alternatively, yet less plausible, studies have shown that a considerable proportion of patients with IPF present with subclinical renal failure in the context of systemic vasculitis, mainly microscopic polyangiitis [8] [9] [10] . The contribution of a clinically occult autoimmune process to fibrotic lung development and progression with multi-systemic projections should also be acknowledged. Next-generation sequencing can expedite the identification of a specific endotype of patients with IPF that are susceptible to renal impairment or drug-induced nephrotoxicity as it has been demonstrated with telomerase mutation carriers showing enhanced susceptibility to hematological complications and renal failure, requiring renal dialysis following lung transplantation [11] .
The demonstration that an extrapulmonary comorbid condition of IPF predicts clinical outcome better than established lung functional prognosticators, such as %DL CO and 6-minute walking distance, should raise the awareness of clinicians to anticipate, monitor, manage, or even prevent systemic manifestations of IPF. This evidence is also supported by epidemiological data showing that a substantial minority (almost 20%) of patients with IPF die due to nonrespiratory comorbid conditions [12] . Comorbidity assessment and management lie at the core of an optimal therapeutic approach of IPF and should be aggressively pursued [13] .
Despite relative enthusiasm, data arising from the current study present with major limitations that should be addressed cautiously. First, this was a single-center retrospective analysis that exhibited common methodological caveats observed in similar approaches, including inability to distinguish between phenomena and epiphenomena and to support cause-causality associations, as well as introduction of potential selection bias. Consequently, statistical associations do not necessarily indicate biological linkage, and, therefore, CKD may simply represent an agerelated bystander of the fibrotic process or a consequence of comorbidity-related drug toxicity. Second, the study analysis is severely hampered by the short duration of outcome observation (mean follow-up period of almost 2 years). Third, methodological caveats on the glomerular filtration rate measurement (the authors excluded serum cystatin C in their estimations) as well as missing data on levels of albuminuria should also be acknowledged. To this end, these observations require further investigation and validation in larger multicenter prospective studies to extract clinically meaningful outcomes.
In conclusion, the current study by Ikezoe et al. [7] , though underpowered, single-center, and retrospective, highlights the necessity for clinicians to treat IPF as a systemic age-related disease, and, thus, it is prudent to monitor and manage these patients for extrapulmonary manifestations to reduce the overall morbidity and mortality and apply individually tailored treatments [14] . The conundrum of disease management and prognostication of IPF can be resolved if we try to connect the dots outside the confines of the square defined by the dots themselves, as it happens with Christopher Columbus's egg puzzle.
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